Association of peroxisome proliferator-activated receptors/retinoic acid receptors with renal diseases

References

• Lamers C, Schubert-Zsilavecz M, Merk D. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present). Expert Opin Ther Pat 2012;22:803–41
   PubMed Web of Science ®Google Scholar
• Fucci A, Colangelo T, Votino C, et al. The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer. PPAR Res 2012;2012:242498
   PubMed Web of Science ®Google Scholar
• Mandard S, Patsouris D. Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. PPAR Res 2013;2013:613864
   PubMed Web of Science ®Google Scholar
• Tsukahara T, Haniu H, Matsuda Y. PTB-associated splicing factor (PSF) is a PPARgamma-binding protein and growth regulator of colon cancer cells. PLoS One 2013;8:e58749
   Google Scholar
• Takada I, Yogiashi Y, Kato S. Signaling crosstalk between PPARgamma and BMP2 in mesenchymal stem cells. PPAR Res 2012;2012:607141
   Google Scholar
• Ramirez A, Ballard EN, Roman J. TGFbeta1 controls PPARgamma expression, transcriptional potential, and activity, in part, through smad3 signaling in murine lung fibroblasts. PPAR Res 2012;2012:375876
   Google Scholar
• Duong V, Rochette-Egly C. The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim Biophys Acta 2011;1812:1023–31
   PubMed Web of Science ®Google Scholar
• Long YB, Qin YH, Zhou TB, Lei FY. Association of retinoic acid receptors with extracellular matrix accumulation in rats with renal interstitial fibrosis disease. Int J Mol Sci 2012;13:14073–85
   PubMed Web of Science ®Google Scholar
• Hauksdottir H, Farboud B, Privalsky ML. Retinoic acid receptors beta and gamma do not repress, but instead activate target gene transcription in both the absence and presence of hormone ligand. Mol Endocrinol 2003;17:373–85
   PubMed Web of Science ®Google Scholar
• He BC, Chen L, Zuo GW, et al. Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 2010;16:2235–45
   PubMedGoogle Scholar
• Yang J, Zhou Y, Guan Y. PPARgamma as a therapeutic target in diabetic nephropathy and other renal diseases. Curr Opin Nephrol Hypertens 2012;21:97–105
   PubMed Web of Science ®Google Scholar
• Kim MK, Ko SH, Baek KH, et al. Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes. Korean J Intern Med 2009;24:227–32
   Google Scholar
• Pistrosch F, Passauer J, Herbrig K, et al. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy. Horm Metab Res 2012;44:914–18
   Google Scholar
• Tang SC, Leung JC, Chan LY, et al. Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: role of STAT1 inhibition and nephrin restoration. Am J Nephrol 2010;32:145–55
   Google Scholar
• Chodavarapu H, Grobe N, Somineni HK, et al. Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS One 2013;8:e62833
   PubMed Web of Science ®Google Scholar
• Bilan VP, Salah EM, Bastacky S, et al. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol 2011;210:293–308
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhu S, Chen J, et al. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care 2012;35:1388–93
   Google Scholar
• Zhou XJ, Cheng FJ, Qi YY, et al. FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy. PLoS One 2013;8:e61208
   PubMed Web of Science ®Google Scholar
• Song J, Sakatsume M, Narita I, et al. Peroxisome proliferator-activated receptor gamma C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy. Clin Genet 2003;64:398–403
   PubMed Web of Science ®Google Scholar
• Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma C161→T polymorphism and coronary artery disease. Cardiovasc Res 1999;44:588–94
   PubMed Web of Science ®Google Scholar
• Xiao J, Leung JC, Chan LY, et al. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy. Nephrol Dial Transplant 2009;24:2067–77
   PubMed Web of Science ®Google Scholar
• Lai KN, Chan LY, Guo H, et al. Additive effect of PPAR-gamma agonist and ARB in treatment of experimental IgA nephropathy. Pediatr Nephrol 2011;26:257–66
   PubMed Web of Science ®Google Scholar
• Collino M, Patel NS, Lawrence KM, et al. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia--reperfusion. Kidney Int 2005;68:529–36
   Google Scholar
• Betz B, Schneider R, Kress T, et al. Rosiglitazone affects nitric oxide synthases and improves renal outcome in a rat model of severe ischemia/reperfusion injury. PPAR Res 2012;2012:219319
   Google Scholar
• Reel B, Guzeloglu M, Bagriyanik A, et al. The effects of PPAR-gamma agonist pioglitazone on renal ischemia/reperfusion injury in rats. J Surg Res 2013;182:176–84
   PubMed Web of Science ®Google Scholar
• Zhu C, Huang S, Yuan Y, et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARgamma. Am J Pathol 2011;178:2020–31
   PubMed Web of Science ®Google Scholar
• Yuan Y, Zhang A, Huang S, et al. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling. Am J Physiol Renal Physiol 2011;300:F393–402
   Google Scholar
• Zou R, Xu G, Liu XC, et al. PPARgamma agonists inhibit TGF-beta-PKA signaling in glomerulosclerosis. Acta Pharmacol Sin 2010;31:43–50
   Google Scholar
• Calkin AC, Giunti S, Jandeleit-Dahm KA, et al. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 2006;21:2399–405
   PubMed Web of Science ®Google Scholar
• Zhou TB, Ou C, Luo CP, Xu HL. Protective effects of PPARgamma agonist in glomerulosclerosis rats induced by adriamycin. Ren Fail 2012;34:940–1
   Web of Science ®Google Scholar
• Yoshihara D, Kurahashi H, Morita M, et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 2011;300:F465–74
   PubMed Web of Science ®Google Scholar
• Lin Q, Gu Y, Ma J, Lin SY. Protection of rosiglitazone against renal interstitial lesion and its mechanism. Zhonghua Yi Xue Za Zhi 2005;85:1618–24
   PubMedGoogle Scholar
• Chung BH, Li C, Sun BK, et al. Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. Am J Transplant 2005;5:1856–67
   PubMed Web of Science ®Google Scholar
• Duester G. Retinoic acid synthesis and signaling during early organogenesis. Cell 2008;134:921–31
   PubMed Web of Science ®Google Scholar
• Kam RK, Deng Y, Chen Y, Zhao H. Retinoic acid synthesis and functions in early embryonic development. Cell Biosci 2012;2:11
   PubMed Web of Science ®Google Scholar
• Marletaz F, Holland LZ, Laudet V, Schubert M. Retinoic acid signaling and the evolution of chordates. Int J Biol Sci 2006;2:38–47
   Google Scholar
• Noy N. Between death and survival: retinoic acid in regulation of apoptosis. Annu Rev Nutr 2010;30:201–17
   PubMed Web of Science ®Google Scholar
• Zhou TB, Drummen GP, Qin YH. The controversial role of retinoic Acid in fibrotic diseases: analysis of involved signaling pathways. Int J Mol Sci 2012;14:226–43
   PubMed Web of Science ®Google Scholar
• Ratnam KK, Feng X, Chuang PY, et al. Role of the retinoic acid receptor-alpha in HIV-associated nephropathy. Kidney Int 2011;79:624–34
   Google Scholar
• Zhong Y, Wu Y, Liu R, et al. Novel retinoic acid receptor alpha agonists for treatment of kidney disease. PLoS One 2011;6:e27945
   Google Scholar
• Schaier M, Liebler S, Schade K, et al. Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. J Mol Med (Berl) 2004;82:116–25
   PubMed Web of Science ®Google Scholar
• He JC, Lu TC, Fleet M, et al. Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol 2007;18:93–102
   PubMed Web of Science ®Google Scholar
• Zhou TB. Signaling pathways of PAX2 and its role in renal interstitial fibrosis and glomerulosclerosis. J Recept Signal Transduct Res 2012;32:298–303
   PubMed Web of Science ®Google Scholar
• Zhou TB. Signaling pathways of apoE and its role of gene expression in glomerulus diseases. J Recept Signal Transduct Res 2013;33:73–8
   PubMed Web of Science ®Google Scholar
• Zhou TB, Qin YH. The signaling pathways of LMX1B and its role in glomerulosclerosis. J Recept Signal Transduct Res 2012;32:285–9
   PubMed Web of Science ®Google Scholar
• Zhou TB, Qin YH. The potential mechanism for the different expressions of gelatinases induced by all-trans retinoic acid in different cells. J Recept Signal Transduct Res 2012;32:129–33
   PubMed Web of Science ®Google Scholar
• Zhou TB, Qin YH. Signaling pathways of prohibitin and its role in diseases. J Recept Signal Transduct Res 2013;33:28–36
   PubMed Web of Science ®Google Scholar
• Tabe Y, Konopleva M, Andreeff M, Ohsaka A. Effects of PPARgamma ligands on leukemia. PPAR Res 2012;2012:483656
   Google Scholar
• Kamel-Reid S, Zhang T, Wells RA. Expression of NPM-RARalpha fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis. Oncogene 2003;22:6424–35
   PubMed Web of Science ®Google Scholar
• Tabe Y, Konopleva M, Kondo Y, et al. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biol Ther 2007;6:1967–77
   PubMed Web of Science ®Google Scholar
• James SY, Lin F, Kolluri SK, et al. Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. Cancer Res 2003;63:3531–8
   PubMed Web of Science ®Google Scholar